Advertisement

Document › Details
bioMérieux S.A.. (1/19/17). "Press Release: bioMérieux – Fourth-Quarter 2016 Business Review". Marcy l’Étoile.
![]() |
Organisation | bioMérieux S.A. (Euronext: BIM) |
Group | Mérieux (Group) | |
Organisation 2 | Biotheranostics Inc. | |
![]() |
Product | in vitro diagnostics (IVD) |
Product 2 | FilmArray® PCR test (product series) | |
![]() |
Person | Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology) |
> Remarkable growth in sales in 2016, up 9.6% like-for-like, lifted by all regions and all strategic lines:
€2,103 million in sales
Up 7.1% as reported
> Strong contribution from the Americas region to Group sales growth
> Success for FilmArray® in molecular biology, with sales at almost €250 million for full-year 2016
> bioMérieux expects contributive operating income before non-recurring items to be slightly above its previous target, moving closer to €300 million
Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux's excellent sales dynamic helped drive organic sales growth of 9.6% and confirms the relevance of our positioning as a specialist in infectious diseases. Given the firm fourth-quarter performance, contributive operating income before non-recurring items should come in slightly higher than our previous estimate. In this favorable environment, the Company will continue to pursue its strategic investments in order to innovate and provide its customers with high value-added medical solutions, making a lasting contribution to improved patient care."
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the twelve months ended December 31, 2016.
SALES
Consolidated sales amounted to €2,103 million in 2016, versus €1,965 million in 2015. Year-on-year organic sales growth (i.e., at constant exchange rates and scope of consolidation) outperformed objectives at 9.6%, led by an acceleration of around 500bp driven by FilmArray® sales. In a volatile currency environment, reported sales growth came to 7.1%, held back by a negative currency effect of around €33 million, as well as the change in scope resulting primarily from the deconsolidation of bioTheranostics as of January 1, 2016.
Download [ www.biomerieux.com/sites/corporate/files/news-event-press-release/biomerieux_pr_sales_q4_2016.pdf ]
Record changed: 2017-02-09 |
Advertisement
![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px](/banner/iito-business-intelligence-20220406-650-200-lse-life-sciences-europe.jpg)
More documents for Mérieux (Group)
- [1] Weezion S.A.S.. (6/1/22). "Press Release: Weezion, a French MedTech Start-up, Announces Capital Investment from bioMérieux". Lyon....
- [2] bioMérieux S.A.. (3/18/22). "Press Release: bioMérieux Receives FDA 510(k) Clearance for Its VITEK MS PRIME New MALDI-TOF Mass Spectrometry Identification System". Marcy l’Étoile....
- [3] bioMérieux S.A.. (6/6/19). "Press Release: bioMérieux Increases Its Holding in Hybiome from 54% to 67%". Marcy l’Étoile....
- [4] bioMérieux S.A.. (4/24/19). "Press Release: bioMérieux – First-Quarter 2019 Business Review". Marcy l’Étoile....
- [5] bioMérieux S.A.. (4/15/19). "Press Release: “Global-PPS”, a Survey of Antibiotic Use and Bacterial Resistance in Hospitals Worldwide, Tops the 200,000 Patients". Marcy l’Étoile & Antwerp....
- [6] bioMérieux S.A.. (4/1/19). "Press Release: University of Antwerp, bioMérieux, and Wellcome Trust to Coordinate VALUE-Dx, a European Public-Private Partnership to Fight Antimicrobial Resistance through Diagnostics". Antwerp, London & Marcy l’Eoile....
- [7] bioMérieux S.A.. (3/19/19). "Press Release: Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury". Deerfield, IL & Marcy l’Etoile....
- [8] bioMérieux S.A.. (2/27/19). "Press Release: bioMérieux – 2018 Financial Results"....
- [9] bioMérieux S.A.. (2/7/19). "Press Release: bioMérieux Acquires Invisible Sentinel, a US-based Company Specialized in Food and Beverage Molecular Testing". Marcy l’Étoile....
- [10] bioMérieux S.A.. (11/13/18). "Press Release: bioMérieux Launches the BioFire FilmArray Pneumonia Panels with FDA Clearance and CE Marking". Marcy l’Étoile....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement
![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x300px](/banner/iito-business-intelligence-20220406-650-300-lse-life-sciences-europe.jpg)
» top